Serum tetranectin is a significant prognostic marker in ovarian cancer patients

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 2, 2010, Pages 190-198

  Begum, Farah Diba ^a   Høgdall, Estrid ^b,c   Christensen, Ib Jarle ^d   Kjaer, Susanne Krger ^a,b   Blaakaer, Jan ^e   Christensen, Lise ^a   Høgdall, Claus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d FINSEN LABORATORY   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Ovarian cancer; Prognosis; Survival; Tetranectin

Indexed keywords

TETRANECTIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; FEMALE; HOSPITAL DEPARTMENT; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

CA-125 ANTIGEN; CARCINOMA; CASE-CONTROL STUDIES; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LECTINS, C-TYPE; MIDDLE AGED; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PREOPERATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; TUMOR MARKERS, BIOLOGICAL;

EID: 76449103619     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016340903530936     Document Type: Article

References (35)

1. Kjaerbye-Thygesen A, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, et al. Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:798-803.
2. NORDCAN, Version 3.4. Available online at: http://wwwdep. iarc.fr/nordcan.htm. (accessed on May 14, 2009).
3. Dansk Gynækologisk Cancer Database, Årsrapport 2006-2007. ISSN: 1902-7877.
4. Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. CA Cancer J Clin. 1995;45:88-101.
5. Bjorge T, Engeland A, Sundfor K, Trope CG. Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-1994 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand. 1998;77:777-781
6. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139-266.
7. Høgdall CK, Christensen L, Clemmensen I. The prognostic value of tetranectin immunoreactivity and plasma tetranectin in patients with ovarian cancer. Cancer. 1993;72:2415-2422 (Pubitemid 23299607)
8. Høgdall CK, Høgdall EV, Hørding U, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Pre-operative plasma tetranectin as a prognostic marker in ovarian cancer patients. Scand J Clin Lab Invest. 1993;53:741-746 (Pubitemid 23350712)
9. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003;98:66-73.
10. Høgdall CK, Nørgaard-Pedersen B, Mogensen O. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res. 2002;22:1765-1768
11. Bast RC Jr, Klug TL, St JE, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887
12. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epitheliumrelated antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2:275-285
13. McGuckin MA, Layton GT, Bailey MJ, Hurst T, Khoo SK, Ward BG. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma - comparison with CA125. Gynecol Oncol. 1990;37:165-171
14. Petri AL, Høgdall E, Christensen IJ, Kjaer SK, Blaakaer J, Høgdall CK. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS. 2006;114: 359-363
15. Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1995;86:259-264
16. Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, et al. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. J Clin Oncol. 2005;23:5938-5942
17. Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG. Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol. 1992;79:1002-1010
18. Makar AP. Prognostic studies in cancer of the ovary and fallopian tube with emphasis on the CA125 antigen on the CA125 antigen and c-erbB-2 oncogene. Acta Obstet Gynecol Scand. 1995;74:238-240
19. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100:59-64.
20. Høgdall CK, Hørding U, Nørgaard-Pedersen B, Toftager-Larsen K, Clemmensen I. Serum tetranectin and CA-125 used to monitor the course of treatment in ovarian cancer patients. Eur J Obstet Gynecol Reprod Biol. 1994;57:175-178
21. Høgdall EVS, Høgdall CK, Christensen L, Glud E, Blaakaer J, Bock JE, et al. Distribution of p53 Codon 72 Polymorp-hisms in Ovarian Tumour Patients and their Prognostic Significance in Ovarian Cancer Patients. Anticancer Res. 2002;22: 1859-1864
22. Høgdall CK, Høgdall EV, Hørding U, Daugaard S, Clemmensen I, Nørgaard-Pedersen B, et al. Plasma tetranectin and ovarian neoplasms. Gynecol Oncol. 1991;43: 103-107
23. Clemmensen I, Lund LR, Christensen L, Andreasen PA. A tetranectin-related protein is produced and deposited in extracellular matrix by human embryonal fibroblasts. Eur J Biochem. 1991;195:735-741
24. Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE. Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur J Biochem. 2003;270:1850-1854
25. Diaz VM, Planaguma J, Thomson TM, Reventos J, Paciucci R. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology 2002;122:809-819
26. Peterson HI, Kjartansson I, Korsan-Bengtsen K, Rudenstam CM, Zettergren L. Fibrinolysis in human malignant tumors. Acta Chir Scand. 1973;139:219-223
27. Hedner U, Nilsson IM. Clinical experience with determination of fibrinogen degradation products. Acta Med Scand. 1971;189:471-477
28. Deng X, Høgdall EV, Høgdall CK, Nørgaard-Pedersen B, Jørgensen M, Nielsen H, et al. The Prognostic Value of Pretherapeutic Tetranectin and CA-125 in Patients with Relapse of Ovarian Cancer. Gynecol Oncol. 2000;79:416-419
29. Begum FD, Høgdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, et al. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res. 2004;24:1981-1985
30. Høgdall CK, Høgdall EVS, Hørding U, Toftager-Larsen K, Arends J, Nørgaard-Pedersen B, et al. The use of tetranectin, CA125 and CASA to predict residual tumor and survival at second and third look operations for ovarian cancer. Acta Oncol. 1996;35:63-69
31. Aletti GD, Dowdy SC, Podrats KC, Cliby WA. Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system. Gynecol Oncol. 2007;105:84-89
32. Pomel C, Barton DP, McNeish I, Shepherd J. A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG. 2008;115:808-810
33. Onda T, Matsumoto K, Shibata T, Sato A, Fukuda H, Konishi I;Japan Clinical Oncology Group. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Jpn J Clin Oncol. 2008;38:74-77
34. Vergote I, Trope CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, et al. EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IVovarian, fallopian tube and peritoneal cancer (OVCA). Abstract available online at: http://www.multiwebcast.com/igcs/ 2008/12th/ 2717/ignace.b.vergote.eortc-gcg.ncic-ctg.randomised.trial. comparing.primary. html. (accessed on May 14, 2009).
35. Möbus V, Kreienberg R, Crombach G, Würz H, Caffier H, Kaesemann H, et al. Evaluation of CA125 as a prognostic and predictive factor in ovarian cancer. J Tumor Marker Oncol. 1988;3:251-258